{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:01:02Z","timestamp":1782853262645,"version":"3.54.5"},"reference-count":69,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>von Willebrand disease (VWD) constitutes the most common inherited human bleeding disorder. Partial quantitative von Willebrand factor (VWF) deficiency is responsible for the majority of VWD cases. International guidelines recommend that patients with mild to moderate reductions in plasma VWF antigen (VWF:Ag) levels (typically in the range of 30-50 IU\/dL) should be diagnosed with low VWF. Over the past decade, a series of large cohort studies have provided significant insights into the biological mechanisms involved in type 1 VWD (plasma VWF:Ag levels &amp;lt;30 IU\/dL). In striking contrast, however, the pathogenesis underpinning low VWF has remained poorly understood. Consequently, low VWF patients continue to present significant clinical challenges with respect to genetic counseling, diagnosis, and management. For example, there is limited information regarding the relationship between plasma VWF:Ag levels and bleeding phenotype in subjects with low VWF. In addition, it is not clear whether patients with low VWF need treatment. For those patients with low VWF in whom treatment is deemed necessary, the optimal choice of therapy remains unknown. However, a number of recent studies have provided important novel insights into these clinical conundrums and the molecular mechanisms responsible for the reduced levels observed in low VWF patients. These emerging clinical and scientific findings are considered in this review, with particular focus on pathogenesis, diagnosis, and clinical management of low VWF.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002038","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T13:37:33Z","timestamp":1594906653000},"page":"3191-3199","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Low VWF: insights into pathogenesis, diagnosis, and clinical management"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0309-3313","authenticated-orcid":false,"given":"James S.","family":"O\u2019Donnell","sequence":"first","affiliation":[{"name":"Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland; National Coagulation Centre, St James\u2019s Hospital, Dublin, Ireland; and National Children\u2019s Research Centre, Our Lady\u2019s Children\u2019s Hospital Crumlin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,7,14]]},"reference":[{"issue":"21","key":"2020071609365422200_B1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"von Willebrand\u2019s disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"2020071609365422200_B2","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","article-title":"von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends","volume":"125","author":"Lenting","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2020071609365422200_B3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","article-title":"Epidemiological investigation of the prevalence of von Willebrand\u2019s disease","volume":"69","author":"Rodeghiero","year":"1987","journal-title":"Blood"},{"issue":"1","key":"2020071609365422200_B4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1538-7836.2009.03661.x","article-title":"The prevalence of symptomatic von Willebrand disease in primary care practice","volume":"8","author":"Bowman","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2020071609365422200_B5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"issue":"4","key":"2020071609365422200_B6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","article-title":"The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology","volume":"167","author":"Laffan","year":"2014","journal-title":"Br J Haematol"},{"issue":"10","key":"2020071609365422200_B7","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2020071609365422200_B8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3324\/haematol.2012.077263","article-title":"Principles of care for the diagnosis and treatment of von Willebrand disease","volume":"98","author":"Castaman","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"2020071609365422200_B9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ajh.21405","article-title":"Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI\/NIH guidelines","volume":"84","author":"Nichols","year":"2009","journal-title":"Am J Hematol"},{"issue":"1","key":"2020071609365422200_B10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood-2006-05-021105","article-title":"The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study","volume":"109","author":"James","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2020071609365422200_B11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood-2006-05-020784","article-title":"Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)","volume":"109","author":"Goodeve","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2020071609365422200_B12","first-page":"630","article-title":"An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease","volume":"96","author":"Cumming","year":"2006","journal-title":"Thromb Haemost"},{"issue":"1","key":"2020071609365422200_B13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1160\/TH15-04-0282","article-title":"Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): proposal for a new diagnostic paradigm","volume":"115","author":"Batlle","year":"2016","journal-title":"Thromb Haemost"},{"issue":"20","key":"2020071609365422200_B14","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1182\/blood-2015-10-673681","article-title":"Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States","volume":"127","author":"Flood","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2020071609365422200_B15","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood-2002-09-2892","article-title":"von Willebrand disease type 1: a diagnosis in search of a disease","volume":"101","author":"Sadler","year":"2003","journal-title":"Blood"},{"issue":"10","key":"2020071609365422200_B16","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/j.1538-7836.2004.00933.x","article-title":"Slippery criteria for von Willebrand disease type 1","volume":"2","author":"Sadler","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"26","key":"2020071609365422200_B17","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2014-02-557264","article-title":"The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease","volume":"123","author":"Federici","year":"2014","journal-title":"Blood"},{"issue":"14","key":"2020071609365422200_B18","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/bloodadvances.2018017418","article-title":"Significant gynecological bleeding in women with low von Willebrand factor levels","volume":"2","author":"Lavin","year":"2018","journal-title":"Blood Adv"},{"issue":"21","key":"2020071609365422200_B19","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1182\/blood-2017-05-786699","article-title":"Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels","volume":"130","author":"Lavin","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2020071609365422200_B20","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood-2018-09-874636","article-title":"Increased galactose expression and enhanced clearance in patients with low von Willebrand factor","volume":"133","author":"Aguila","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2020071609365422200_B21","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1111\/j.1538-7836.2008.03182.x","article-title":"Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease","volume":"6","author":"Bowman","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2020071609365422200_B22","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"Rodeghiero","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2020071609365422200_B23","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1538-7836.2007.02326.x","article-title":"Risk of excessive bleeding associated with marginally low von Willebrand factor and mild platelet dysfunction","volume":"5","author":"Gudmundsdottir","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2020071609365422200_B24","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1160\/TH07-06-0419","article-title":"Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes","volume":"99","author":"Lethagen","year":"2008","journal-title":"Thromb Haemost"},{"issue":"4","key":"2020071609365422200_B25","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1538-7836.2006.01847.x","article-title":"A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)","volume":"4","author":"Tosetto","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2020071609365422200_B26","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1365-2141.2009.08052.x","article-title":"Platelet von Willebrand factor\u2013structure, function and biological importance","volume":"148","author":"McGrath","year":"2010","journal-title":"Br J Haematol"},{"issue":"25","key":"2020071609365422200_B27","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1182\/blood-2013-04-496851","article-title":"Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis","volume":"122","author":"McGrath","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2020071609365422200_B28","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/jth.13696","article-title":"von Willebrand factor and inflammation","volume":"15","author":"Kawecki","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"19","key":"2020071609365422200_B29","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood-2015-11-636464","article-title":"Emerging roles for hemostatic dysfunction in malaria pathogenesis","volume":"127","author":"O\u2019Sullivan","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2020071609365422200_B30","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2015-07-654921","article-title":"A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria","volume":"127","author":"O\u2019Regan","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2020071609365422200_B31","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2010-01-264507","article-title":"Endothelial von Willebrand factor regulates angiogenesis","volume":"117","author":"Starke","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2020071609365422200_B32","doi-asserted-by":"crossref","first-page":"e0161310","DOI":"10.1371\/journal.pone.0161310","article-title":"Diagnostic value of measuring platelet von Willebrand factor in von Willebrand disease","volume":"11","author":"Casonato","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"2020071609365422200_B33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1055\/s-0037-1616250","article-title":"Analysis of thyroid hormone status in 131 consecutive individuals with low von Willebrand factor levels","volume":"93","author":"Franchini","year":"2005","journal-title":"Thromb Haemost"},{"issue":"2","key":"2020071609365422200_B34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.15565","article-title":"von Willebrand factor clearance - biological mechanisms and clinical significance","volume":"183","author":"O\u2019Sullivan","year":"2018","journal-title":"Br J Haematol"},{"key":"2020071609365422200_B35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/jth.12226","article-title":"Clearance of von Willebrand factor","volume":"11","author":"Casari","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2020071609365422200_B36","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/jth.12875","article-title":"von Willebrand factor arginine 1205 substitution results in accelerated macrophage-dependent clearance in vivo","volume":"13","author":"Rawley","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"19","key":"2020071609365422200_B37","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/blood-2014-09-603241","article-title":"von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease","volume":"125","author":"Sanders","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2020071609365422200_B38","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2012-09-455089","article-title":"VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease","volume":"121","author":"Eikenboom","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2020071609365422200_B39","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/blood-2006-04-015065","article-title":"Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival","volume":"108","author":"Haberichter","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2020071609365422200_B40","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1538-7836.2006.01860.x","article-title":"Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study","volume":"4","author":"James","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2020071609365422200_B41","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1538-7836.2006.01823.x","article-title":"Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD","volume":"4","author":"Eikenboom","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2020071609365422200_B42","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/jth.14304","article-title":"Genetic regulation of plasma von Willebrand factor levels in health and disease","volume":"16","author":"Swystun","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"19","key":"2020071609365422200_B43","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1182\/blood-2012-10-415000","article-title":"Elucidating the role of carbohydrate determinants in regulating hemostasis: insights and opportunities","volume":"121","author":"Preston","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2020071609365422200_B44","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/j.1537-2995.2006.00975.x","article-title":"ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?","volume":"46","author":"Jenkins","year":"2006","journal-title":"Transfusion"},{"issue":"6","key":"2020071609365422200_B45","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","article-title":"The effect of ABO blood group on the diagnosis of von Willebrand disease","volume":"69","author":"Gill","year":"1987","journal-title":"Blood"},{"issue":"2","key":"2020071609365422200_B46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/hq0202.103997","article-title":"Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels","volume":"22","author":"O\u2019Donnell","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"2020071609365422200_B47","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-11-122945","article-title":"A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor","volume":"111","author":"Gallinaro","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2020071609365422200_B48","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1182\/blood-2004-08-3080","article-title":"Determinants of ABH expression on human blood platelets","volume":"105","author":"Cooling","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2020071609365422200_B49","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood.V96.4.1574","article-title":"Blood group A and B antigens are strongly expressed on platelets of some individuals","volume":"96","author":"Curtis","year":"2000","journal-title":"Blood"},{"issue":"7","key":"2020071609365422200_B50","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/ATVBAHA.115.305337","article-title":"ABO blood group as a model for platelet glycan modification in arterial thrombosis","volume":"35","author":"Zhong","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"2020071609365422200_B51","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1182\/blood-2018-06-855528","article-title":"Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function","volume":"133","author":"Dunne","year":"2019","journal-title":"Blood"},{"issue":"13","key":"2020071609365422200_B52","doi-asserted-by":"crossref","first-page":"E3221","DOI":"10.3390\/ijms20133221","article-title":"Influence of ABO locus on PFA-100 collagen-ADP closure time is not totally dependent on the von Willebrand Factor. Results of a GWAS on GAIT-2 project phenotypes","volume":"20","author":"Pujol-Moix","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"15","key":"2020071609365422200_B53","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood-2016-04-709436","article-title":"N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance","volume":"128","author":"Chion","year":"2016","journal-title":"Blood"},{"issue":"15","key":"2020071609365422200_B54","doi-asserted-by":"crossref","first-page":"10042","DOI":"10.1073\/pnas.142005099","article-title":"Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands","volume":"99","author":"Ellies","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2020071609365422200_B55","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nm1760","article-title":"The Ashwell receptor mitigates the lethal coagulopathy of sepsis","volume":"14","author":"Grewal","year":"2008","journal-title":"Nat Med"},{"issue":"7","key":"2020071609365422200_B56","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/jth.14471","article-title":"von Willebrand factor sialylation-a critical regulator of biological function","volume":"17","author":"Ward","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"15","key":"2020071609365422200_B57","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1016\/S0021-9258(19)63384-3","article-title":"Relationship of sialic acid to function and in vivo survival of human factor VIII\/von Willebrand factor protein","volume":"252","author":"Sodetz","year":"1977","journal-title":"J Biol Chem"},{"issue":"12","key":"2020071609365422200_B58","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/jth.13537","article-title":"N-linked glycan truncation causes enhanced clearance of plasma-derived von Willebrand factor","volume":"14","author":"O\u2019Sullivan","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2020071609365422200_B59","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1182\/blood-2017-06-787853","article-title":"A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance","volume":"131","author":"Ward","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2020071609365422200_B60","first-page":"916","article-title":"Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations","volume":"99","author":"Millar","year":"2008","journal-title":"Thromb Haemost"},{"issue":"1","key":"2020071609365422200_B61","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/bloodadvances.2019000992","article-title":"Low VWF levels in children and lack of association with bleeding in children undergoing tonsillectomy","volume":"4","author":"Gill","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2020071609365422200_B62","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/asheducation-2009.1.106","article-title":"Low von Willebrand factor: sometimes a risk factor and sometimes a disease","volume":"2009","author":"Sadler","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2020071609365422200_B63","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/asheducation-2016.1.683","article-title":"New treatment approaches to von Willebrand disease","volume":"2016","author":"Lavin","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"2020071609365422200_B64","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2018-10-844936","article-title":"How I treat low von Willebrand factor levels","volume":"133","author":"Lavin","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2020071609365422200_B65","first-page":"984","article-title":"Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history","volume":"104","author":"S\u00e1nchez-Luceros","year":"2010","journal-title":"Thromb Haemost"},{"issue":"5","key":"2020071609365422200_B66","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/jth.13294","article-title":"Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms","volume":"14","author":"Alb\u00e1nez","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2020071609365422200_B67","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/hae.12664","article-title":"Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease","volume":"21","author":"Rydz","year":"2015","journal-title":"Haemophilia"},{"issue":"7","key":"2020071609365422200_B68","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jth.12586","article-title":"von Willebrand disease and aging: an evolving phenotype","volume":"12","author":"Sanders","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2020071609365422200_B69","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bjh.15277","article-title":"Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease","volume":"182","author":"Atiq","year":"2018","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/3191\/1748625\/advancesadv2020002038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/3191\/1748625\/advancesadv2020002038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T10:15:02Z","timestamp":1616667302000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/13\/3191\/461317\/Low-VWF-insights-into-pathogenesis-diagnosis-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,14]]},"references-count":69,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002038","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,14]]}}}